Triple therapy with telaprevir: Results in hepatitis C virus-genotype 1 infected relapsers and non-responders

Liver International

Volumn 32, Issue SUPPL. 1, 2012, Pages 44-50

  Forestier, Nicole ^a   Zeuzem, Stefan ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Chronic hepatitis C; Interferon; Non response; Relapse; Ribavirin; Therapy; Treatment options

Indexed keywords

PEGINTERFERON ALPHA2A; POLYPROTEIN; RIBAVIRIN; TELAPREVIR;

ALOPECIA; ANEMIA; ANORECTAL DISEASE; ASTHENIA; COUGHING; DIARRHEA; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG WITHDRAWAL; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HEADACHE; HEPATITIS C; HUMAN; INSOMNIA; LIVER CIRRHOSIS; LIVER FIBROSIS; MONOTHERAPY; NAUSEA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN PROCESSING; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; VIRUS GENOME; VIRUS REPLICATION;

ADULT; AGED; ANEMIA; ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; SERINE PROTEINASE INHIBITORS; SKIN DISEASES; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS REPLICATION; YOUNG ADULT;

EID: 84855334387     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02720.x     Document Type: Review

References (17)

1. McHutchison JG, Lawitz E, Shiffman M. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93.
2. Asselah T, Bieche I, Narguet S, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008; 57: 516-24.
3. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008; 105: 7034-9.
4. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
5. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
6. Bartenschlager R, Frese M, Pietschmann T. Novel insights into hepatitis C virus replication and persistence. Adv Virus Res 2004; 63: 71-180.
7. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-63.
8. De Francesco R, Carfi A. Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv Drug Deliv Rev 2007; 59: 1242-62.
9. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-303.
10. Berg T, McHutchison JG, Adda N, Zeuzem S, Beaumont M. SVR with telaprevir, peginterferon alfa-2a and ribavirin in HCV patients with well-characterized prior null response, partial response, viral breakthrough or relapse after PR. Hepatology 2010; 52(Suppl.1:S2): 1A-1352A. Abstract.
11. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
12. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
13. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
14. Pol S, Aerssens J, Zeuzem S, et al. Similar SVR rates in IL28B CC, CT or TT prior relapsers, partial-or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the REALIZE study. J Hepatol 2011; 54(Suppl.1): 13A. Abstract.
15. Foster G, Zeuzem S, Andreone P, Pol S, Lawitz EJ, et al. Subanalyses of the telaprevir lead-in arm in the REALIZE study: response at week 4 is not a substitute for prior null response categorization. J Hepatol 2011; 54(Suppl.1): 6A. Abstract.
16. Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011; 140: 459-68.
17. Zeuzem S, Asselah T, Angus P, et al. Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients with Chronic HCV infection. Gastroenterology 2011; 141: 2047-55.